Perspective Therapeutics, Inc.
AMEX:CATXMedical - Devices
+$0.02 today
- Market cap
- $94.20M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$107.27
Volume 2.69M
Average 1.44M
CATX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Perspective Therapeutics, Inc.AMEX: CATX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $20.25M rose 41.3% year over year, behind the +76.6% change in trailing-twelve-month research & development. Sequentially, it fell 38.5% from the prior quarter. Over 3 fiscal years it compounded at +218.7% a year.
Context
- Research & development amounted to 9526.6% of revenue in FY2025, up 6662.9 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +41.3% toward the trailing-twelve-month pace of +76.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 84.22M USD
- Year-over-year change
- +102.3%
- 4-year CAGR
- +139.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 84.22M | +102.3% |
| FY2024 | 2024-12-31 | 41.64M | +95.4% |
| FY2023 | 2023-12-31 | 21.31M | +719.0% |
| FY2022 | 2022-12-31 | 2.6M | +0.8% |
| FY2021 | 2022-06-30 | 2.58M | — |
Research & Development vs competitors
How CATX compares with its peers on the latest reported figures
- CATX's LTM Mar 2026 research & development of $85.68M is the 2nd highest of the 5 companies compared; the peer median is $24.47M.
- Its year-over-year change of +76.6% is the 2nd highest of 5, against a peer median of +11.4%.
- Research & development amounts to 13864.6% of revenue for CATX, versus a peer median of 33.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $229.1M | +8.2% | +2.9% | 34.0% | |
| LTM Mar 2026 | $85.68M | +76.6% | +218.7% | 13864.6% | |
| LTM Mar 2026 | $34.06M | +124.4% | +16.3% | 37.7% | |
| LTM Mar 2026 | $14.89M | -1.7% | -11.2% | 33.2% | |
| LTM Mar 2026 | $6.76M | +14.7% | +31.0% | 30.0% | |
| Peer median (excluding CATX) | $24.47M | +11.4% | +9.6% | 33.6% | |
Competitors are the stored peer set for CATX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2022 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.8M | 7.1M | 1.43M | 1.45M | 884K |
| Cost of Revenue | 6.18M | 5.47M | 0 | 0 | 0 |
| Gross Profit | 4.62M | 1.63M | 1.43M | (852K) | (2.37M) |
| Gross Margin | 42.8% | 23.0% | 100.0% | -58.6% | -267.8% |
| Research & Development | 2.58M | 2.6M | 21.31M | 41.64M | 84.22M |
| Selling, General & Admin | 9.43M | 14.21M | 21.06M | 26.61M | 30.23M |
| Operating Expenses | 12.01M | 17.43M | 42.38M | 92.34M | 113.56M |
| Depreciation & Amortization | 248K | 344K | 981K | 2.31M | 3.25M |
| EBITDA | (7.39M) | (14.84M) | (39.96M) | 10.46M | (100.8M) |
| EBITDA Margin | -68.5% | -208.9% | -2786.6% | 719.3% | -11402.8% |
| Operating Income | (7.39M) | (15.18M) | (40.94M) | 10.46M | (113.56M) |
| Operating Margin | -68.5% | -213.7% | -2855.0% | 719.3% | -12846.6% |
| Interest Income | 119K | 1.12M | 934K | 10.52M | 8.11M |
| Interest Expense | 119K | 0 | 84K | (48K) | 376K |
| Other Income / Expenses | 119K | 512K | 835K | (91.84M) | 9.14M |
| Income Before Tax | (7.27M) | (14.67M) | (40.11M) | (81.38M) | (104.43M) |
| Pre-Tax Margin | -67.4% | -206.5% | -2796.8% | -5596.7% | -11813.1% |
| Income Tax Expense | (119K) | 0 | (2.65M) | (2.1M) | (793K) |
| Net Income | (7.15M) | (14.67M) | (46.51M) | (79.28M) | (103.12M) |
| Net Margin | -66.3% | -206.5% | -3243.2% | -5452.5% | -11665.3% |
| EPS (Basic) | (0.13) | (0.27) | (0.85) | (1.23) | (1.40) |
| EPS (Diluted) | (0.13) | (0.27) | (0.85) | (1.23) | (1.40) |
| Weighted Avg Shares | 54.91M | 54.91M | 54.91M | 64.43M | 73.81M |
| Weighted Avg Shares (Diluted) | 54.91M | 54.91M | 54.91M | 64.43M | 73.81M |
Perspective Therapeutics, Inc.
AMEX:CATX
Intrinsic Alpha fair value
Locked
Current Price
$0.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.